New combo therapy aims to control hard-to-treat prostate cancer
NCT ID NCT07250542
First seen Jan 11, 2026 · Last updated Apr 23, 2026 · Updated 18 times
Summary
This study tests whether adding fasudil hydrochloride to immunotherapy can help control metastatic castration-resistant prostate cancer in patients who have already tried standard treatments. About 30 adults aged 18 to 85 will receive the combination therapy. Researchers will measure PSA levels and quality of life to see if the treatment is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Zhongda Hospital
RECRUITINGNanjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.